HomeMy WebLinkAboutState of Idaho Opioid Intrastate Allocation Agreement Item#12.
Mayor Robert E. Simison
E IDIAN*w�- City Council Members:
Treg Bernt Brad Hoaglun
Joe Borton Jessica Perreault
H Luke Cavener Liz Strader
TO: Robert E. Simison and Members of the City Council
FROM: Kurt Starman, Deputy City Attorney and Tracy Basterrechea, Police Chief
RE: Idaho Opioid Settlement Intrastate Allocation Agreement
DATE: November 22, 2021
MEMORANDUM
The State of Idaho recently joined two nationwide settlement agreements that resolve several opioid-
related claims against Johnson&Johnson and three opioid distributors. Unless the City intends to pursue
its own claims against Johnson&Johnson and the distributors, it would be advantageous for the City to
join these settlement agreements, as well.
Based on the default allocation formula in the settlement agreements, the City would receive
approximately$431,000 over 17 years to combat the opioid crisis. These funds could be used, for
example, to assist the Meridian Anti-Drug Coalition with its efforts.
As noted above, the settlement agreements include a default allocation formula. However, the settlement
agreements also allow each state to develop its own allocation formula. Consequently, the State of Idaho
is proposing an Intrastate Allocation Agreement that would modify the default allocation formula. Under
the default allocation formula, settlement funds would be distributed as follows: 15 percent to the State;
15 percent to cities and counties; and 70 percent to a trust fund which would be administered by a
committee. Under the Intrastate Allocation Agreement, the State would receive 40%; cities and counties
would receive 40%; and the State's regional health districts would receive 20%. Under this formula, it is
anticipated the City would receive approximately $1,150,000 over 17 years (as opposed to $431,000
under the default allocation formula). Further, the City would be eligible to receive additional funding
associated with other pending opioid claims, including claims against Purdue Pharma. One disadvantage,
however, is that the Intrastate Allocation Agreement includes additional reporting and accounting
requirements, including a requirement for an audit each year that could cost up to $7,000. Nevertheless,
the Intrastate Allocation Agreement is superior to the default allocation formula because it would provide
far more funding to the City to combat the opioid crisis.
The nationwide settlement agreements are not yet in final form. It is anticipated, however, that the
settlement agreements will be ready for the City Council's consideration within the next 45 days. In the
interim, the State is requesting that cities and counties approve the Intrastate Allocation Agreement by
December 3, 2021. Therefore, Staff recommends that the City Council approve the Intrastate Allocation
Agreement.
Ciity Attorney's Office . 33 E. Broadway Avenue, Suite#306 . Meridian, ID 83642 page 167
Phone 208-898-5506 . www.meridiancity.org
Item#12.
IDAHO OPIOID SETTLEMENT INTRASTATE ALLOCATION AGREEMENT
BETWEEN THE STATE OF IDAHO, HEALTH DISTRICTS,AND ELIGIBLE LOCAL
GOVERNMENTS
The State,by and through the Attorney General, and the undersigned Participating Local
Governments and Participating Health Districts, in consideration of the promises and the mutual
covenants set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, enter into this Idaho Opioid Settlement Intrastate
Allocation Agreement("Agreement") and covenant and agree as follows:
General Principles
Capitalized terms not defined below have the meanings set forth in the Definitions section of
this Agreement.
• The people of the State of Idaho and Idaho communities have been harmed by the opioid
epidemic, which was caused by misconduct committed by certain entities within the
Pharmaceutical Supply Chain.
• The State of Idaho, ex rel. Lawrence Wasden,Attorney General (the "State"), and certain
Participating Local Governments are separately engaged in litigation seeking to hold the
Pharmaceutical Supply Chain Participants accountable for the damage they caused.
• The State, Health Districts, and the Participating Local Governments share a common
desire to abate and alleviate the impacts of the Pharmaceutical Supply Chain Participants'
misconduct throughout the State of Idaho.
• Settlements resulting from the investigations and litigation with Johnson&Johnson,
AmerisourceBergen, Cardinal Health, and McKesson have taken the form of National
Settlement Agreements.
• This Agreement is intended to facilitate compliance by the State and by the Participating
Local Governments with the terms of the National Settlement Agreements and, to the
extent appropriate, with other settlements related to the opioid epidemic reached by both
the State and Participating Local Governments.
• Idaho's share of settlement funds from the National Settlement Agreements will be
maximized only if all Idaho Local Governments of a certain size participate in the
settlements.
• The National Settlement Agreements will set a default allocation between each State and
its political subdivisions unless they enter into a state-specific agreement regarding the
distribution and use of settlement amounts (a"State-Subdivision Agreement"), and this
Agreement is intended to serve as such a State-Subdivision Agreement under the National
Settlement Agreements.
• The State and certain Participating Local Governments are also involved in ongoing
litigation with other Pharmaceutical Supply Chain Participants and the aforementioned
investigations and litigation have caused some Pharmaceutical Supply Chain Participants
1 Page 168
Item#12.
to declare bankruptcy, and they may cause additional entities to declare bankruptcy in the
future.
• This Agreement is also intended to serve as a State-Subdivision Agreement for future
resolutions of claims through settlement or in bankruptcy court where both the State and
Participating Local Governments have filed suit concerning alleged misconduct in the
manufacture, marketing, promotion, distribution, or dispensing of an opioid analgesic and
the resolution of such claims provide for payments (including payments through a trust)
to both the State and Participating Local Governments and allow for the allocation
between a state and its political subdivisions to be set through a state-specific agreement
("Future Resolutions"). This includes but is not limited to serving as a Statewide
Abatement Agreement under the bankruptcy resolutions in In re Purdue Pharma L.P., et.
al., Case No. 19-23649 (RDD) (Bankr. S.D.N.Y.) and In re Mallinckrodt PLC, et al.,
Case No. 20-12522 (JTD) (Bankr. D. Del.).
• The State is participating in litigation and investigations of certain other Pharmaceutical
Supply Chain Participants for which Participating Local Governments are not involved
and resolution of such claims are not subject to this Agreement.
A. Definitions
As used in this Agreement
1. The terms "Future Resolutions,""State," and"State-Subdivision Agreement" are defined
under General Principles in this Agreement.
2. "Approved Purpose(s)" shall mean those uses identified in the agreed Opioid Abatement
Strategies attached as Exhibit A.
3. "Governing Body"means(1)for a county,the board of county commissioners; (2) for a
municipality, the city council; and(3) for a health district, the district board of health.
4. "Health Districts" shall mean the seven regional public health districts created pursuant to
Title 39, Chapter 4, Idaho Code.
5. "Litigating Participating Local Governments"means the Participating Local
Governments that filed an initial complaint in the Opioid Litigation by September 1,
2020.
6. "MDL Litigation"means the matter captioned In re: National Prescription Opiate
Litigation, MDL 2804 (N.D. Ohio).
7. "National Settlement Agreements"means the national opioid settlement agreements dated
July 21, 2021, with Settling Defendants Johnson&Johnson and Distributors
AmerisourceBergen, Cardinal Health and McKesson as well as their subsidiaries,
affiliates, officers, and directors named in the National Settlement Agreements, including
all amendments thereto.
2 Page 169
Item#12.
8. "Non-Litigating Participating Local Governments"means the Participating Local
Governments who are not Litigating Participating Local Governments.
9. "Non-Participating Health District"means a Health District who is not a Participating
Health District.
10. "Non-Participating Local Government"means a city or county who is not a Participating
Local Government.
11. "Opioid Funds" shall mean monetary amounts obtained through the National Settlement
Agreements and Future Resolutions as defined in this Agreement. Not included are funds
paid to the State to resolve State claims against Pharmaceutical Supply Chain Participants
for which Participating Local Governments were not a party or did not otherwise
participate. Also not included are funds paid to Participating Local Governments solely to
resolve Participating Local Governments' claims against Pharmaceutical Supply Chain
Participants, not claims by the State.
12. "Opioid Litigation"means existing or potential legal claims against Pharmaceutical
Supply Chain Participants seeking to hold them accountable for the damage caused by
their misfeasance, nonfeasance, and malfeasance relating to the unlawful manufacture,
marketing,promotion, distribution, or dispensing of prescription opioids.
13. "Participating Local Government" shall mean a county or city within the geographic
boundaries of the State who participates in this Agreement and who participates in the
National Settlement Agreements and/or Future Resolutions. A Local Government may be
a Participating Local Government under the National Settlement Agreements and not for
some or all Future Resolutions or vice versa if it does not choose to participate in the
National Settlement Agreements or some or all Future Resolutions. Eligible local
governments include: (1) all counties within the State of Idaho; and(2) cities within the
State of Idaho who are either involved in Opioid Litigation or who have a population of
over 10,000.1 For the avoidance of doubt, a county or city must sign this Agreement to
become a"Participating Local Government."
14. "Participating Health District" shall mean a Health District who agrees to participate in
this Agreement and in the National Settlement Agreements and/or Future Resolutions. A
Health District may be a Participating Health District under the National Settlement
Agreements and not for some or all Future Resolutions or vice versa if it does not
choose to participate in the National Settlement Agreements or some or all Future
Resolutions. For the avoidance of doubt, a Health District must sign this Agreement to
become a "Participating Health District."
15. "Parties" shall mean the State, Participating Health Districts, and Participating Local
Governments.
16. "Pharmaceutical Supply Chain" shall mean the process and channels through which licit
opioids are manufactured, marketed, promoted, distributed, or dispensed.
'All references to population in this Agreement shall refer to published U. S.Census Bureau population estimates as
of July 1,2019,released March 2020,and shall remain unchanged during the term of this Agreement. These
estimates can currently be found at https://www.census.gov/data/datasets/time-series/demo/popest/2010s-counties-
total.html.
3 Page 170
Item#12.
17. "Pharmaceutical Supply Chain Participant" shall mean any entity that engages in or has
engaged in the manufacture, marketing,promotion, distribution, or dispensing of licit
opioids.
18. "Public Health District Fund"means the fund established under Idaho Code § 39-422.
19. "State-Directed Opioid Settlement Fund"means the fund established under Idaho Code
§ 57-825.
B.Allocation of Settlement Proceeds
1. All Opioid Funds shall be divided with forty percent(40%)to the State ("State Share");
forty percent(40%)to the Participating Local Governments ("LG Share"); and twenty
percent (20%)to the Participating Health Districts ("HD Share").2
2. All Opioid Funds, regardless of allocation, shall only be utilized for Approved Purposes
included in Exhibit A. Compliance with this requirement shall be verified through
reporting, as set out in Section D of this Agreement. The parties acknowledge that under
the terms of the National Settlement Agreements there are certain allowed non-Opioid
Remediation expenditures which require additional reporting under those agreements.
Additionally, the parties acknowledge that under the National Settlement Agreements no
less than eighty-five percent(85%) of the funds must be used for Opioid Remediation
with at least seventy percent(70%) of funds used solely for future Opioid Remediation.
3. Receipt and Distribution of the State Share: Funds will be deposited into the State-
Directed Opioid Settlement Fund after payment of attorney's fees and costs to the State's
outside counsel as provided in Section C.
4. Receipt and Distribution of the LG Share: The LG Share shall be paid by check or
wire transfer directly to the Participating Local Governments after payment of funds into
the Idaho Attorney Fee Back-Stop Fund as provided in Section C.S. Each Participating
Local Government will be allocated the percentage of the remaining LG Share as set forth
in Exhibit B. Payments will be made directly to each Participating Local Government,
and subject to the mechanisms for auditing and reporting set forth below to provide
accountability and transparency to the public to verify appropriate use of the funds. Each
Participating Local Government may elect to have its share reallocated to
the Participating Health District within which it is located. Any funds allocated to a Non-
Participating Local Government or to Participating Local Government that cannot be paid
under the terms of this Agreement, the National Settlement Agreements, or a Future
Resolution shall be allocated to the Participating Health District in which the Local
Government is located. A county and some or all of its incorporated cities, in so far as all
are Participating Local Governments, may enter into a separate intracounty allocation
agreement to modify how the total funds available to said county and cities under Exhibit
B are allocated amongst themselves. For the avoidance of doubt, a county or city must
agree in writing in order to have its share reallocated under an intracounty allocation
agreement. Such an agreement shall not modify any of the other terms or requirements of
the National Settlements, Future Resolutions, or this Agreement.
z This Agreement assumes that any opioid settlement for Native American Tribes will be dealt with separately.
4 Page 171
Item#12.
5. Receipt and Distribution of the HD Share: The HD Share shall be paid directly to the
Public Health District Fund after payment of attorney's fees and costs to the State's
outside counsel as provided in Section C. Funds would be allocated among each
Participating Health District based on the aggregate of the percentages allocated to the
Local Governments within each such Health District as determined pursuant to paragraph
4 above, and as set forth specifically in Exhibit C. These funds would also be subject to
the mechanism for auditing and reporting set forth below to provide accountability and
transparency to the public to verify appropriate use of the funds. Any funds allocated
under Exhibit C to a Non-Participating Health District shall be allocated to the
Participating Health Districts in proportion to the allocation set forth in Exhibit C. If any
Participating Health District ceases to exist, the funds shall be allocated between the
remaining Participating Health Districts as provided for in this paragraph. If all
Participating Health Districts cease to exist, the HD Share will be split equally between
the State Share and the LG Share.
6. The State, Participating Health Districts, and Participating Local Governments may
coordinate for implementation of opioid remediation strategies. The Parties agree that
collaboration promotes the effective use of Opioid Funds and that they will coordinate
with trusted partners to collect and share information about successful regional and other
high-impact strategies and opioid treatment programs.
C. Payment of Counsel and Opioid Litigation Expenses
1. The Parties recognize that the funds being shared under this agreement were obtained
through significant effort by outside counsel retained by the State and Litigating
Participating Local Governments in the Opioid Litigation.
2. The National Settlement Agreements provide for the payment of all or a portion of the
attorney's fees and legal expenses owed by the State and Litigating Participating Local
Governments to outside counsel retained for Opioid Litigation. To effectuate this the
court in the MDL Litigation has established a common benefit fund to compensate
attorneys for services rendered and expenses incurred that have benefitted plaintiffs
generally in the litigation (the"Common Benefit Fund"). The Parties anticipate that
Future Resolutions may also provide for the payment of all or a portion of attorney's fees
and legal expenses.
3. If funds for attorney's fees and expenses under the National Settlement Agreements,
Future Resolutions, and the Common Benefit Fund are insufficient to cover the attorney
fee obligations of the State and Litigating Participating Local Governments (as modified
by Judge Polster's August 6, 2021 Order in the MDL Litigation), the deficiencies will be
covered as set forth in further detail below.
4. Deficiencies for outside counsel for the State shall be paid as follows:
a. As a means of covering any deficiencies in payment for outside counsel retained
by the State specifically for Opioid Litigation, five percent (5%) of the State Share
and five percent(5%) of the HD Share from the National Settlements and Future
Resolutions not exempt under Section C.7 shall be sent to outside counsel prior to
payment to the State-Directed Opioid Settlement Fund and the Public Health
5 Page 172
Item#12.
District Fund. No funds from the LG Share shall be used to pay attorney's fees for
outside counsel for the State.
b. Outside counsel for the State shall maintain the funds in a separate trust account,
not comingled with other funds. Outside counsel for the State shall make
application to the Idaho Attorney General's Office for payments out of the trust
account for a deficiency, meaning the difference between what their fee
agreements would entitle them to (as limited by this Section) minus what they
have already collected from attorney fee funds established under the National
Settlement Agreements and Future Resolutions and the Common Benefit Fund.
c. Any remaining funds in the account in excess of the amounts needed to cover the
deficiency in attorney's fees as provided in this Section shall revert back to the
State Share and HD Share and shall be allocated as provided in Section B.
d. Outside counsel for the State shall make a report to the Idaho Attorney General's
Office every two (2) years setting forth the balance of the trust account and any
outstanding potential deficiencies in order for the Idaho Attorney General's Office
to assess whether the trust fund is overfunded and funds should be reverted or
underfunded and more funding should be provided.
5. Deficiencies for outside counsel for Litigating Participating Local Governments shall be
paid as follows:
a. As a means of covering any deficiencies in payment for outside counsel retained
by Participating Local Governments specifically for the Opioid Litigation, a
supplemental Idaho Attorney Fee Back-Stop Fund shall be established.
b. The Idaho Attorney Fee Back-Stop Fund shall be funded by ten percent (10%) of
the LG Share from the National Settlement Agreements and Future Resolutions
not exempt under Section C.7. No funds from the State Share and HD Share shall
be used to pay attorney's fees to counsel for the Litigating Participating Local
Governments. If some or all of the Participating Local Governments believe that
ten percent(10%) will not be sufficient to cover a deficiency in attorney's fees
those Participating Local Governments can enter into an agreement to hold back
an additional amount of up to two and one-half percent (2.5%) of the LG Share
allocated to those Participating Local Governments under Exhibit B to be put into
the Idaho Attorney Fee Back-Stop Fund. For the avoidance of doubt, no funds
above the original ten percent (10%) shall be held back to fund the Idaho Attorney
Fee Back-Stop Fund from the share allocated to a Participating Local Government
under Exhibit B without their express written agreement, and in no circumstance
may the overall amount withheld exceed tweleve and one-half percent(12.5%).
c. Payments out of the Idaho Attorney Fee Back-Stop Fund shall be determined by
majority vote of a committee ("Idaho Attorney Fee Back-Stop Fund Committee")
consisting of three members:
i. One (1) member appointed by the Litigating Participating Local
Governments;
6 Page 173
Item#12.
ii. One (1) member appointed by the Non-Litigating Participating Local
Governments; and
iii. One (1) member jointly appointed by all of the other members listed
above.
d. Outside counsel retained by Litigating Participating Local Governments may
apply to the Idaho Attorney Fee Back-Stop Fund only for a deficiency, meaning
the difference between what their fee agreements would entitle them to (as limited
by this Section) minus what they have already collected from attorney fee funds
established under the National Settlement Agreements and Future Resolutions and
the Common Benefit Fund. For the avoidance of doubt, collectively, outside
counsel for Litigating Participating Local Governments are limited to being paid,
at most, and assuming adequate funds are available under the National Settlement
Agreements, Future Resolutions, the Common Benefit Fund and the Idaho
Attorney Fee Back-Stop Fund, attorney's fees totaling fifteen percent(15%) of the
LG Share.
e. Any funds remaining in the Idaho Attorney Fee Back-Stop Fund in excess of the
amounts needed to cover the deficiency in attorney's fees as provided in this
Section shall revert back to the LG Share and shall be allocated as provided in
Section B.
f. Applications for funds from the Idaho Attorney Fee Back-Stop Fund must be
supported by an affidavit of the attorney setting forth the basis and method of
computation for the attorney's fees request. The Idaho Attorney Fee Back-Stop
Fund Committee may also request additional documentation to support an
application.
g. The Idaho Attorney Fee Back-Stop Fund Committee shall meet at least once
annually to review applications and determine whether to release and/or revert
funds. Every two (2) years, the Idaho Attorney Fee Back-Stop Fund Committee
shall assess the amount remaining in the fund to determine if it is overfunded or
underfunded.
6. The Parties agree that should a Future Resolution not provide for any payment of
attorney's fees, the parties will confer and in good faith consider an amendment to this
Section to provide for additional funds.
7. This Section(Section C) shall not apply to settlements involving McKinsey or the
bankruptcy proceedings In re Purdue Pharma L.P., et. al., Case No. 19-23649 (RDD)
(Bankr. S.D.N.Y.) and In re Mallinckrodt PLC, et al., Case No. 20-12522 (JTD) (Bankr.
D. Del) or other Future Resolutions in so far as the express terms limit the payment of
attorney's fees and would not allow for the payment of attorney's fees from the State
Share, LG Share, and HD Share.
7 Page 174
Item#12.
D. Compliance Reporting and Accountability
1. Participating Health Districts, Participating Local Governments, and the State shall
maintain, for a period of at least five (5) years, records of Opioid Fund expenditures and
documents underlying those expenditures, so that it can be verified that funds are being or
have been utilized in a manner consistent with the National Settlement Agreements,
Future Resolutions, and this Agreement. During and after the term of this Agreement, the
Attorney General shall have access to persons and records related to this Agreement and
expenditures of Opioid Funds.
2. Opioid Funds can only be used for an Approved Purpose when the Governing Body of a
Participating Local Government or Participating Health District includes in its budget or
passes a separate resolution authorizing the expenditure of a stated amount of Opioid
Funds for that Approved Purpose during a specified period of time. The budget or
resolution should: (1) indicate that it is an authorization for expenditure of Opioid Funds,
(2) state the specific Approved Purpose the governing body intends to fund as identified
in Exhibit A, and(3) state the amount dedicated to each Approved Purpose for a stated
period of time.
3. Opioid Funds are subject to the financial audit requirements for Participating Local
Governments and Participating Health Districts as provided under Idaho Law, and shall
be separately accounted for in any such audit. If any such audit reveals an expenditure
inconsistent with the terms of this Agreement, the Participating Local Government or
Participating Health District shall immediately report the finding to the Idaho Attorney
General.
4. For every fiscal year in which a Participating Local Government or Participating Health
District receives, holds, or spends Opioid Funds, the Local Government or Health District
must submit an annual financial report specifying the activities and amounts it has
funded. The annual financial report shall be provided to the Idaho Attorney General by
emailing the report to oopioidsettlement@ag.idaho.gov within ninety(90) days of the last
day of the state fiscal year covered by the report. Each annual financial report must
include the following information: (1)the amount of Opioid Funds available at the
beginning of the fiscal year; (2)the amount of Opioid Funds received during the fiscal
year; (3)the amount of Opioid Funds disbursed or applied during the fiscal year, broken
down by Approved Purposes set forth in Exhibit A; (4)the amount of Opioid Funds
available at the end of the fiscal year. The annual financial reports provided to the Idaho
Attorney General will be made publically available by publication on the Idaho Attorney
General's website https://www.a .ig daho.gov/consumer-protection/opioid-settlement/and
be maintained on that webpage for a period not less than five (5) years. The Attorney
General will also post annual reports of State expenditures of Opioid Funds on the Idaho
Attorney General's website and maintain said reports on the webpage for a period not less
than five (5) years.
5. If the National Settlement Agreements or any Future Resolutions require that a
Participating Local Government or Participating Health District file, post, or provide a
report or other document beyond those described in this Agreement, or if any
Participating Local Government or Participating Health District communicates in writing
8 Page 175
Item#12.
with any national administrator or other entity created or authorized by the National
Settlement Agreements or any Future Resolutions regarding compliance with the
National Settlement Agreement or Future Resolutions, the Participating Local
Government or Participating Health District shall email a copy of any such report,
document, or communication to the Idaho Attorney General at
opioidsettlement@ag.idaho.gov.
6. Every Participating Local Government and Participating Health District shall make a
good faith effort to comply with all of its reporting obligations under this Agreement. A
Participating Local Government or Participating Health District that engages in a good
faith effort to comply with its reporting obligations under Section D.7 and D.8 but fails in
some way to report information in an accurate, timely, or complete manner shall be given
an opportunity to remedy this failure within a reasonable time. A Participating Local
Government or Participating Health District that does not engage in a good faith effort to
comply with its reporting obligations under this Agreement, or that fails to remedy
reporting issues within a reasonable time, may be subject to action for breach of contract.
Notwithstanding anything to the contrary herein, a Participating Local Government or
Participating Health District that is in substantial compliance with the reporting
obligations in this Agreement shall not be considered in breach of this Agreement.
7. If it appears to the State that a Participating Local Government or Participating Health
District is using or has used Opioid Funds for non-Approved Purposes, the State may on
written request seek and obtain the documentation underlying the report(s) described in
this Section (Section D), as applicable. The Participating Local Government or
Participating Health District receiving such request shall have fourteen (14) days to
provide the requested information. The State and the Participating Local Government or
Participating Health District receiving such request may extend the time period for
compliance with the request only upon mutual agreement.
8. Following a request made pursuant to D.7, if the State determines that a Participating
Local Government or Health District spent any Opioid Funds on an expenditure
inconsistent with the terms of this Agreement, the State shall send notice to the
Participating Local Government or Participating Health District of such determination
and allow sixty(60) days to cure the inconsistent expenditure through budget amendment
or repayment. If a Participating Local Government or Participating Health District does
not make the cure within sixty(60) days, the State may(i) reduce future Opioid Fund
payments to that Participating Local Government or Participating Health District by an
amount equal to the inconsistent expenditure; and(ii)to the extent the inconsistent
expenditure is greater than the expected future stream of payments, initiate a process up
to and including litigation to recover the overage. The State may recover any litigation
expenses incurred to recover the funds. Any recovery or redistribution shall be distributed
consistent with Section B.4 above.
E. Other Terms
1. This Agreement shall become effective at the time a sufficient number of local
governments have joined the Agreement to qualify this Agreement as a State-Subdivision
9 Page 176
Item#12.
Agreement under the National Settlement Agreements or any Future Resolutions. If this
Agreement does not thereby qualify as a State-Subdivision Agreement,this Agreement
will have no effect. Once effective, this Agreement will remain in effect until at least one
(1) year after the last date on which any Opioid Funds are spent by Participating Local
Governments and Participating Health Districts pursuant to the National Settlement
Agreements and any Future Resolutions.
2. The Parties agree to make such amendments as necessary to implement the intent of
this agreement. After this Agreement becomes effective, amendments may only be
made to this Agreement if approved in writing by the Attorney General and at least
two-thirds of the Participating Local Governments and Participating Health
Districts.
3. This Agreement shall be governed by and construed under the laws of the State of
Idaho using Idaho law. Any action related to the provisions of this Agreement,
except as otherwise provided in the National Settlement Agreements or Future
Resolutions, must be adjudicated by the Idaho state courts of Ada County in the
State of Idaho.
4. This Agreement does not supersede or alter the terms of the National Settlement
Agreements or any Future Resolutions except to the extent those terms allow for a
State-Subdivision Agreement to do so.
5. If any part of this Agreement is declared invalid or becomes inoperative for any
reason, such invalidity or failure shall not affect the validity and enforceability of
any other provision.
6. This Agreement may be executed in counterparts, each of which shall be deemed an
original and all of which together shall be considered one and the same agreement.
A signature transmitted by facsimile or electronic image shall be deemed an
original signature for purposes of executing this Agreement.
7. Each person signing this Agreement represents that he or she is fully authorized to
enter into the terms and conditions of, and to execute, this Agreement on behalf of
the named governmental entity, and that all necessary approvals and conditions
precedent to his or her execution have been satisfied.
FOR THE STATE OF IDAHO
DATE: October 25, 2021
LAWRENCE G WASDEN
ATTORNEY GENERAL
STATE OF DAHO
[Other Signature Pages to Follow]
10 Page 177
item#12. Exhibit A
Approved Opioid Abatement Strategies
Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder
or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs
or strategies that may include, but are not limited to, the following:
PART ONE: TREATMENT
A. TREAT OPIOID USE DISORDER(OUD)
Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use
Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-
informed programs or strategies that may include, but are not limited to, the following':
1. Expand availability of treatment for OUD and any co-occurring SUD/MH
conditions,including all forms of Medication-Assisted Treatment(MAT)approved
by the U.S. Food and Drug Administration.
2. Support and reimburse evidence-based services that adhere to the American Society
of Addiction Medicine (ASAM) continuum of care for OUD and any co-occurring
SUD/MH conditions
3. Expand telehealth to increase access to treatment for OUD and any co-occurring
SUD/MH conditions, including MAT, as well as counseling, psychiatric support,
and other treatment and recovery support services.
4. Improve oversight of Opioid Treatment Programs(OTPs)to assure evidence-based
or evidence-informed practices such as adequate methadone dosing and low
threshold approaches to treatment.
5. Support mobile intervention,treatment, and recovery services, offered by qualified
professionals and service providers,such as peer recovery coaches,for persons with
OUD and any co-occurring SUD/MH conditions and for persons who have
experienced an opioid overdose.
6. Treatment of trauma for individuals with OUD (e.g., violence, sexual assault,
human trafficking, or adverse childhood experiences) and family members (e.g.,
surviving family members after an overdose or overdose fatality), and training of
health care personnel to identify and address such trauma.
7. Support evidence-based withdrawal management services for people with OUD
and any co-occurring mental health conditions.
'As used in this Exhibit A,words like"expand,""fund,""provide"or the like shall not indicate a preference for new
or existing programs. Priorities will be established through the mechanisms described in the Public Creditor Trust
Distribution Procedures.
A-1
Page 178
item#12. Exhibit A
Approved Opioid Abatement Strategies
8. Training on MAT for health care providers, first responders, students, or other
supporting professionals, such as peer recovery coaches or recovery outreach
specialists, including telementoring to assist community-based providers in rural or
underserved areas.
9. Support workforce development for addiction professionals who work with persons
with OUD and any co-occurring SUD/MH conditions.
10. Fellowships for addiction medicine specialists for direct patient care, instructors,
and clinical research for treatments.
11. Scholarships and supports for behavioral health practitioners or workers involved
in addressing OUD and any co-occurring SUD or mental health conditions,
including but not limited to training, scholarships, fellowships, loan repayment
programs, or other incentives for providers to work in rural or underserved areas.
12. Provide funding and training for clinicians to obtain a waiver under the federal Drug
Addiction Treatment Act of 2000 (DATA 2000) to prescribe MAT for OUD, and
provide technical assistance and professional support to clinicians who have
obtained a DATA 2000 waiver.
13. Dissemination of web-based training curricula, such as the American Academy of
Addiction Psychiatry's Provider Clinical Support Service-Opioids web-based
training curriculum and motivational interviewing.
14. Development and dissemination of new curricula, such as the American Academy
of Addiction Psychiatry's Provider Clinical Support Service for Medication-
Assisted Treatment.
B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY
Support people in recovery from OUD and any co-occurring SUD/MH conditions through
evidence-based or evidence-informed programs or strategies that may include, but are not
limited to, the following:
1. Provide comprehensive wrap-around services to individuals with OUD and any co-
occurring SUD/MH conditions, including housing, transportation, education, job
placement,job training, or childcare.
2. Provide the full continuum of care of treatment and recovery services for OUD and
any co-occurring SUD/MH conditions, including supportive housing,peer support
services and counseling, community navigators, case management, and
connections to community-based services.
3. Provide counseling, peer-support, recovery case management and residential
treatment with access to medications for those who need it to persons with OUD
and any co-occurring SUD/MH conditions.
A-2
Page 179
item#12. Exhibit A
Approved Opioid Abatement Strategies
4. Provide access to housing for people with OUD and any co-occurring SUD/MH
conditions, including supportive housing, recovery housing, housing assistance
programs, training for housing providers, or recovery housing programs that allow
or integrate FDA-approved mediation with other support services.
5. Provide community support services, including social and legal services, to assist
in deinstitutionalizing persons with OUD and any co-occurring SUD/MH
conditions.
6. Support or expand peer-recovery centers,which may include support groups, social
events, computer access, or other services for persons with OUD and any co-
occurring SUD/MH conditions.
7. Provide or support transportation to treatment or recovery programs or services for
persons with OUD and any co-occurring SUD/MH conditions.
8. Provide employment training or educational services for persons in treatment for
or recovery from OUD and any co-occurring SUD/MH conditions.
9. Identify successful recovery programs such as physician, pilot, and college
recovery programs, and provide support and technical assistance to increase the
number and capacity of high-quality programs to help those in recovery.
10. Engage non-profits, faith-based communities, and community coalitions to support
people in treatment and recovery and to support family members in their efforts to
support the person with OUD in the family.
11. Training and development of procedures for government staff to appropriately
interact and provide social and other services to individuals with or in recovery
from OUD, including reducing stigma.
12. Support stigma reduction efforts regarding treatment and support for persons with
OUD, including reducing the stigma on effective treatment.
13. Create or support culturally appropriate services and programs for persons with
OUD and any co-occurring SUD/MH conditions, including new Americans.
14. Create and/or support recovery high schools.
15. Hire or train behavioral health workers to provide or expand any of the services or
supports listed above.
C. CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED
(CONNECTIONS TO CARE)
Provide connections to care for people who have—or at risk of developing—OUD and any
co-occurring SUD/MH conditions through evidence-based or evidence-informed programs
or strategies that may include, but are not limited to, the following:
A-3
Page 180
item#12. Exhibit A
Approved Opioid Abatement Strategies
1. Ensure that health care providers are screening for OUD and other risk factors and
know how to appropriately counsel and treat (or refer if necessary) a patient for
OUD treatment.
2. Fund Screening, Brief Intervention and Referral to Treatment (SBIRT) programs
to reduce the transition from use to disorders,including SBIRT services to pregnant
women who are uninsured or not eligible for Medicaid.
3. Provide training and long-term implementation of SBIRT in key systems (health,
schools,colleges, criminal justice, and probation),with a focus on youth and young
adults when transition from misuse to opioid disorder is common.
4. Purchase automated versions of SBIRT and support ongoing costs of the
technology.
5. Expand services such as navigators and on-call teams to begin MAT in hospital
emergency departments.
6. Training for emergency room personnel treating opioid overdose patients on post-
discharge planning, including community referrals for MAT, recovery case
management or support services.
7. Support hospital programs that transition persons with OUD and any co-occurring
SUD/MH conditions, or persons who have experienced an opioid overdose, into
clinically appropriate follow-up care through a bridge clinic or similar approach.
8. Support crisis stabilization centers that serve as an alternative to hospital emergency
departments for persons with OUD and any co-occurring SUD/MH conditions or
persons that have experienced an opioid overdose.
9. Support the work of Emergency Medical Systems, including peer support
specialists, to connect individuals to treatment or other appropriate services
following an opioid overdose or other opioid-related adverse event.
10. Provide funding for peer support specialists or recovery coaches in emergency
departments, detox facilities, recovery centers, recovery housing, or similar
settings; offer services, supports, or connections to care to persons with OUD and
any co-occurring SUD/MH conditions or to persons who have experienced an
opioid overdose.
11. Expand warm hand-off services to transition to recovery services.
12. Create or support school-based contacts that parents can engage with to seek
immediate treatment services for their child; and support prevention, intervention,
treatment, and recovery programs focused on young people.
13. Develop and support best practices on addressing OUD in the workplace.
A-4
Page 181
item#12. Exhibit A
Approved Opioid Abatement Strategies
14. Support assistance programs for health care providers with OUD.
15. Engage non-profits and the faith community as a system to support outreach for
treatment.
16. Support centralized call centers that provide information and connections to
appropriate services and supports for persons with OUD and any co-occurring
SUD/MH conditions.
D. ADDRESS THE NEEDS OF CRIMINAL-JUSTICE-INVOLVED PERSONS
Address the needs of persons with OUD and any co-occurring SUD/MH conditions who
are involved in, are at risk of becoming involved in, or are transitioning out of the criminal
justice system through evidence-based or evidence-informed programs or strategies that
may include, but are not limited to, the following:
1. Support pre-arrest or pre-arraignment diversion and deflection strategies for
persons with OUD and any co-occurring SUD/MH conditions, including
established strategies such as:
1. Self-referral strategies such as the Angel Programs or the Police Assisted
Addiction Recovery Initiative (PAARI);
2. Active outreach strategies such as the Drug Abuse Response Team(DART)
model;
3. "Naloxone Plus"strategies,which work to ensure that individuals who have
received naloxone to reverse the effects of an overdose are then linked to
treatment programs or other appropriate services;
4. Officer prevention strategies, such as the Law Enforcement Assisted
Diversion(LEAD) model;
5. Officer intervention strategies such as the Leon County,Florida Adult Civil
Citation Network or the Chicago Westside Narcotics Diversion to
Treatment Initiative; or
6. Co-responder and/or alternative responder models to address OUD-related
911 calls with greater SUD expertise.
2. Support pre-trial services that connect individuals with OUD and any co-occurring
SUD/MH conditions to evidence-informed treatment, including MAT, and related
services.
3. Support treatment and recovery courts that provide evidence-based options for
persons with OUD and any co-occurring SUD/MH conditions.
A-5
Page 182
item#12. Exhibit A
Approved Opioid Abatement Strategies
4. Provide evidence-informed treatment, including MAT, recovery support, harm
reduction, or other appropriate services to individuals with OUD and any co-
occurring SUD/MH conditions who are incarcerated in jail or prison.
5. Provide evidence-informed treatment, including MAT, recovery support, harm
reduction, or other appropriate services to individuals with OUD and any co-
occurring SUD/MH conditions who are leaving jail or prison have recently left jail
or prison, are on probation or parole, are under community corrections supervision,
or are in re-entry programs or facilities.
6. Support critical time interventions (CTI), particularly for individuals living with
dual-diagnosis OUD/serious mental illness, and services for individuals who face
immediate risks and service needs and risks upon release from correctional settings.
7. Provide training on best practices for addressing the needs of criminal-justice-
involved persons with OUD and any co-occurring SUD/MH conditions to law
enforcement, correctional, or judicial personnel or to providers of treatment,
recovery,harm reduction,case management,or other services offered in connection
with any of the strategies described in this section.
E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR
FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE
SYNDROME
Address the needs of pregnant or parenting women with OUD and any co-occurring
SUD/MH conditions, and the needs of their families, including babies with neonatal
abstinence syndrome (NAS), through evidence-based or evidence-informed programs or
strategies that may include, but are not limited to, the following:
I. Support evidence-based or evidence-informed treatment, including MAT,recovery
services and supports, and prevention services for pregnant women — or women
who could become pregnant — who have OUD and any co-occurring SUD/MH
conditions, and other measures to educate and provide support to families affected
by Neonatal Abstinence Syndrome.
2. Expand comprehensive evidence-based treatment and recovery services, including
MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions
for up to 12 months postpartum.
3. Training for obstetricians or other healthcare personnel that work with pregnant
women and their families regarding treatment of OUD and any co-occurring
SUD/MH conditions.
4. Expand comprehensive evidence-based treatment and recovery support for NAS
babies; expand services for better continuum of care with infant-need dyad; expand
long-term treatment and services for medical monitoring of NAS babies and their
families.
A-6
Page 183
item#12. Exhibit A
Approved Opioid Abatement Strategies
5. Provide training to health care providers who work with pregnant or parenting
women on best practices for compliance with federal requirements that children
born with Neonatal Abstinence Syndrome get referred to appropriate services and
receive a plan of safe care.
6. Child and family supports for parenting women with OUD and any co-occurring
SUD/MH conditions.
7. Enhanced family supports and child care services for parents with OUD and any
co-occurring SUD/MH conditions.
8. Provide enhanced support for children and family members suffering trauma as a
result of addiction in the family; and offer trauma-informed behavioral health
treatment for adverse childhood events.
9. Offer home-based wrap-around services to persons with OUD and any co-occurring
SUD/MH conditions, including but not limited to parent skills training.
10. Support for Children's Services—Fund additional positions and services, including
supportive housing and other residential services, relating to children being
removed from the home and/or placed in foster care due to custodial opioid use.
PART TWO: PREVENTION
F. PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE
PRESCRIBING AND DISPENSING OF OPIOIDS
Support efforts to prevent over-prescribing and ensure appropriate prescribing and
dispensing of opioids through evidence-based or evidence-informed programs or strategies
that may include, but are not limited to, the following:
I. Fund medical provider education and outreach regarding best prescribing practices
for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain
from the U.S. Centers for Disease Control and Prevention, including providers at
hospitals (academic detailing).
2. Training for health care providers regarding safe and responsible opioid
prescribing, dosing, and tapering patients off opioids.
3. Continuing Medical Education(CME) on appropriate prescribing of opioids.
4. Support for non-opioid pain treatment alternatives, including training providers to
offer or refer to multi-modal, evidence-informed treatment of pain.
5. Support enhancements or improvements to Prescription Drug Monitoring Programs
(PDMPs), including but not limited to improvements that:
A-7
Page 184
item#12. Exhibit A
Approved Opioid Abatement Strategies
1. Increase the number of prescribers using PDMPs;
2. Improve point-of-care decision-making by increasing the quantity, quality,
or format of data available to prescribers using PDMPs, by improving the
interface that prescribers use to access PDMP data, or both; or
3. Enable states to use PDMP data in support of surveillance or intervention
strategies, including MAT referrals and follow-up for individuals identified
within PDMP data as likely to experience OUD in a manner that complies
with all relevant privacy and security laws and rules.
6. Ensuring PDMPs incorporate available overdose/naloxone deployment data,
including the United States Department of Transportation's Emergency Medical
Technician overdose database in a manner that complies with all relevant privacy
and security laws and rules.
7. Increase electronic prescribing to prevent diversion or forgery.
8. Educate Dispensers on appropriate opioid dispensing.
G. PREVENT MISUSE OF OPIOIDS
Support efforts to discourage or prevent misuse of opioids through evidence-based or
evidence-informed programs or strategies that may include, but are not limited to, the
following:
1. Fund media campaigns to prevent opioid misuse.
2. Corrective advertising or affirmative public education campaigns based on
evidence.
3. Public education relating to drug disposal.
4. Drug take-back disposal or destruction programs.
5. Fund community anti-drug coalitions that engage in drug prevention efforts.
6. Support community coalitions in implementing evidence-informed prevention,
such as reduced social access and physical access, stigma reduction — including
staffing, educational campaigns, support for people in treatment or recovery, or
training of coalitions in evidence-informed implementation,including the Strategic
Prevention Framework developed by the U.S. Substance Abuse and Mental Health
Services Administration(SAMHSA).
7. Engage non-profits and faith-based communities as systems to support prevention.
8. Fund evidence-based prevention programs in schools or evidence-informed school
and community education programs and campaigns for students, families, school
A-8
Page 185
item#12. Exhibit A
Approved Opioid Abatement Strategies
employees, school athletic programs, parent-teacher and student associations, and
others.
9. School-based or youth-focused programs or strategies that have demonstrated
effectiveness in preventing drug misuse and seem likely to be effective in
preventing the uptake and use of opioids.
10. Create of support community-based education or intervention services for families,
youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.
11. Support evidence-informed programs or curricula to address mental health needs
of young people who may be at risk of misusing opioids or other drugs, including
emotional modulation and resilience skills.
12. Support greater access to mental health services and supports for young people,
including services and supports provided by school nurses, behavioral health
workers or other school staff, to address mental health needs in young people that
(when not properly addressed) increase the risk of opioid or another drug misuse.
H. PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)
Support efforts to prevent or reduce overdose deaths or other opioid-related harms through
evidence-based or evidence-informed programs or strategies that may include, but are not
limited to, the following:
1. Increase availability and distribution of naloxone and other drugs that treat
overdoses for first responders, overdose patients, individuals with OUD and their
friends and family members, schools, community navigators and outreach workers,
persons being released from jail or prison, or other members of the general public.
2. Public health entities providing free naloxone to anyone in the community.
3. Training and education regarding naloxone and other drugs that treat overdoses for
first responders, overdose patients, patients taking opioids, families, schools,
community support groups, and other members of the general public.
4. Enable school nurses and other school staff to respond to opioid overdoses, and
provide them with naloxone, training, and support.
5. Expand, improve, or develop data tracking software and applications for
overdoses/naloxone revivals.
6. Public education relating to emergency responses to overdoses.
7. Public education relating to immunity and Good Samaritan laws.
8. Educate first responders regarding the existence and operation of immunity and
Good Samaritan laws.
A-9
Page 186
item#12. Exhibit A
Approved Opioid Abatement Strategies
9. Syringe service programs and other evidence-informed programs to reduce harms
associated with intravenous drug use, including supplies, staffing, space, peer
support services,referrals to treatment, fentanyl checking, connections to care, and
the full range of harm reduction and treatment services provided by these programs.
10. Expand access to testing and treatment for infectious diseases such as HIV and
Hepatitis C resulting from intravenous opioid use.
11. Support mobile units that offer or provide referrals to harm reduction services,
treatment, recovery supports, health care, or other appropriate services to persons
that use opioids or persons with OUD and any co-occurring SUD/MH conditions.
12. Provide training in harm reduction strategies to health care providers, students,peer
recovery coaches,recovery outreach specialists, or other professionals that provide
care to persons who use opioids or persons with OUD and any co-occurring
SUD/MH conditions.
13. Support screening for fentanyl in routine clinical toxicology testing.
PART THREE: OTHER STRATEGIES
I. I. FIRST RESPONDERS
In addition to items in section C,D and H relating to first responders,support the following:
I. Educate law enforcement or other first responders regarding appropriate practices
and precautions when dealing with fentanyl or other drugs.
2. Provision of wellness and support services for first responders and others who
experience secondary trauma associated with opioid-related emergency events.
J. LEADERSHIP, PLANNING AND COORDINATION
Support efforts to provide leadership, planning, coordination, facilitations, training and
technical assistance to abate the opioid epidemic through activities,programs,or strategies
that may include,but are not limited to, the following:
I. Statewide, regional, local or community regional planning to identify root causes
of addiction and overdose, goals for reducing harms related to the opioid epidemic,
and areas and populations with the greatest needs for treatment intervention
services, and to support training and technical assistance and other strategies to
abate the opioid epidemic described in this opioid abatement strategy list.
2. A dashboard to (a) share reports, recommendations, or plans to spend opioid
settlement funds; (b) to show how opioid settlement funds have been spent; (c) to
report program or strategy outcomes; or(d)to track, share or visualize key opioid-
A-10
Page 187
item#12. Exhibit A
Approved Opioid Abatement Strategies
or health-related indicators and supports as identified through collaborative
statewide, regional, local or community processes.
3. Invest in infrastructure or staffing at government or not-for-profit agencies to
support collaborative, cross-system coordination with the purpose of preventing
overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and
any co-occurring SUD/MH conditions, supporting them in treatment or recovery,
connecting them to care, or implementing other strategies to abate the opioid
epidemic described in this opioid abatement strategy list.
4. Provide resources to staff government oversight and management of opioid
abatement programs.
K. TRAINING
In addition to the training referred to throughout this document, support training to abate
the opioid epidemic through activities,programs,or strategies that may include,but are not
limited to, the following:
1. Provide funding for staff training or networking programs and services to improve
the capability of government, community, and not-for-profit entities to abate the
opioid crisis.
2. Support infrastructure and staffing for collaborative cross-system coordination to
prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-
occurring SUD/MH conditions, or implement other strategies to abate the opioid
epidemic described in this opioid abatement strategy list(e.g., health care, primary
care, pharmacies, PDMPs, etc.).
L. RESEARCH
Support opioid abatement research that may include, but is not limited to, the following:
1. Monitoring, surveillance, data collection and evaluation of programs and
strategies described in this opioid abatement strategy list.
2. Research non-opioid treatment of chronic pain.
3. Research on improved service delivery for modalities such as SBIRT that
demonstrate promising but mixed results in populations vulnerable to
opioid use disorders.
4. Research on novel harm reduction and prevention efforts such as the
provision of fentanyl test strips.
5. Research on innovative supply-side enforcement efforts such as improved
detection of mail-based delivery of synthetic opioids.
A-1 I
Page 188
item#12. Exhibit A
Approved Opioid Abatement Strategies
6. Expanded research on swift/certain/fair models to reduce and deter opioid
misuse within criminal justice populations that build upon promising
approaches used to address other substances(e.g. Hawaii HOPE and Dakota
24/7).
7. Epidemiological surveillance of OUD-related behaviors in critical
populations including individuals entering the criminal justice system,
including but not limited to approaches modeled on the Arrestee Drug
Abuse Monitoring(ADAM) system.
8. Qualitative and quantitative research regarding public health risks and harm
reduction opportunities within illicit drug markets, including surveys of
market participants who sell or distribute illicit opioids.
9. Geospatial analysis of access barriers to MAT and their association with
treatment engagement and treatment outcomes.
A-12
Page 189
EXHIBIT B
Item#12.
ALLOCATION OF LOCAL GOVERNMENT SHARE
Percentage of Local Percentage of Local
Local Government Government Share Local Government Government Share
Ada County, Idaho 13.2776278333% Latah County, Idaho 1.2943861166%
Adams County, Idaho 0.1446831902% Lemhi County, Idaho 0.4880814284%
Ammon City, Idaho 0.0812916024% Lewis County, Idaho 0.2882543555%
Bannock County, Idaho 3.0595589832% Lewiston City, Idaho 2.0176549375%
Bear Lake County, Idaho 0.6082712041% Lincoln County, Idaho 0.1930184422%
Benewah County, Idaho 0.6526829809% Madison County, Idaho 1.2748404845%
Bingham County, Idaho 1.6421270812% Meridian City, Idaho 2.4045650754%
Blackfoot City,Idaho 0.6283857401% Minidoka County,Idaho 0.9140620922%
Blaine County, Idaho 0.9137717551% Moscow City, Idaho 0.6590552650%
Boise City, Idaho 12.7586409110% Mountain Home City, Idaho 0.5706694591%
Boise County, Idaho 0.3309644652% Nampa City, Idaho 3.3274647954%
Bonner County,Idaho 2.5987361786% Nez Perce County, Idaho 1.2765833482%
Bonneville County, Idaho 3.7761253875% Oneida County,Idaho 0.2371656647%
Boundary County, Idaho 0.8788284447% Owyhee County, Idaho 0.5554298409%
Burley City, Idaho 0.4485975363% Payette County, Idaho 1.2750728102%
Butte County, Idaho 0.1839745518% Pocatello City, Idaho 2.9494898116%
Caldwell City,Idaho 1.1958553249% Post Falls City,Idaho 0.6781328826%
Camas County, Idaho 0.0422073443% Power County, Idaho 0.3505171035%
Canyon County, Idaho 5.0120113688% Preston City, Idaho 0.1496220047%
Caribou County, Idaho 0.4396183832% Rexburg City, Idaho 0.1336231941%
Cassia County, Idaho 0.7270235866% Shoshone County, Idaho 1.2841091340%
Chubbuck City, Idaho 0.4841935447% Star City, Idaho 0.0001322772%
Clark County, Idaho 0.0420924425% Teton County, Idaho 0.4258195211%
Clearwater County,Idaho 0.4890418390% Twin Falls City,Idaho 1.8245765222%
Coeur D'Alene City, Idaho 2.7593778237% Twin Falls County, Idaho 3.3104301873%
Custer County, Idaho 0.2133243878% Valley County, Idaho 0.8074710814%
Eagle City, Idaho 0.1711876661% Washington County, Idaho 0.4917358652%
Elmore County, Idaho 0.8899512165%
Franklin County, Idaho 0.5753624958%
Fremont County, Idaho 0.5716071696%
Garden City, Idaho 0.5582782838%
Gem County, Idaho 1.3784025725%
Gooding County, Idaho 0.6966472013%
Hayden City, Idaho 0.0047132146%
Idaho County, Idaho 0.8474305547%
Idaho Falls City, Idaho 3.8875027578%
Jefferson County, Idaho 0.9842670749%
Jerome City, Idaho 0.4169017424%
Jerome County, Idaho 0.6223444291%
Kootenai County, Idaho 5.6394798565%
Kuna City, Idaho 0.1849461724%
B-1
Page 190
Item#12. EXHIBIT C
ALLOCATION OF HEALTH DISTRICT SHARE
Percentage of Health
Health District District Share
District 1 (Panhandle) 14.50%
District 2 (North Central) 6.87%
District 3 (Southwest) 13.38%
District 4 (Central) 31.95%
District 5 (South Central) 10.11%
District 6 (Southeastern) 11.31%
District 7 (Eastern) 11.88%
C-1
Page 191
IDAHO OPIOID SETTLEMENT INTRASTATE ALLOCATION AGREEMENT
BETWEEN THE STATE OF IDAHO, HEALTH DISTRICTS,AND ELIGIBLE LOCAL
GOVERNMENTS
SIGN-ON
By signing below I represent that I am fully authorized to enter into the Idaho Opioid
Settlement Allocation Agreement on behalf on the named governmental entity, and that all
necessary approvals and conditions precedent to my execution have been satisfied.
Signature:
Name: Robert E. Simison
Title: Mayor
Governmental Entity: City of Meridian
Date: 11-30-2021
VOLUNTARY REALLOCATION
[DO NOT FILL OUT UNLESS YOUR GOVERNMENT HAS SIGNED ON ABOVE AND
WISHES TO VOLUNTARILY REALLOCATE ITS SHARE OF FUNDS TO ITS REGIONAL
PUBLIC HEALTH DISTRICT]
By signing below I represent that the named governmental entity does not wish to receive the
funds allocated to it under the Idaho Opioid Settlement Allocation Agreement and has
authorized that its share of funds instead be allocated to the following regional public health
district established under Title 39, Chapter 4, Idaho Code.
Name of Public Health District:
Signature:
Name:
Title:
Governmental Entity:
Date: